Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
From MaRDI portal
Publication:2059113
DOI10.1007/s10260-020-00537-3zbMath1480.62224OpenAlexW3044325711MaRDI QIDQ2059113
Publication date: 13 December 2021
Published in: Statistical Methods and Applications (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/s10260-020-00537-3
Bayesian approachposterior predictive probabilitiesefficacy and toxicity outcomesmultinomial-Dirichlet distributionsingle-arm phase II trials
Cites Work
- Unnamed Item
- Bayesian two-stage design for phase II clinical trials with switching hypothesis tests
- Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
- Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
- Bivariate Sequential Designs for Phase II Trials
- On construction of single‐arm two‐stage designs with consideration of both response and toxicity
- What Does Objective Mean in a Dirichlet‐multinomial Process?